Final analysis of the MAGNOLIA trial: zanubrutinib in marginal zone lymphoma
Final analysis of the MAGNOLIA trial: zanubrutinib in
Clinical findings with sundry targets in various B-cell malignancies
Clinical findings with sundry targets in various B-cel
Follicular lymphoma: bispecific and PI3Kδ-targeted approaches
Follicular lymphoma: bispecific and PI3Kδ-targeted app
New approaches in relapsed and refractory DLBCL
New approaches in relapsed and refractory DLBCL Pol
Chronic lymphocytic leukemia: moving towards new horizons
Chronic lymphocytic leukemia: moving towards new horiz
Further steps to improve efficacy and safety in acute myeloid leukemia
Further steps to improve efficacy and safety in acute
Active monotherapies and combinations in mantle cell lymphoma
Active monotherapies and combinations in mantle cell l
Potential strategies to overcome relapsed and refractory Waldenström’s macroglobulinemia
Potential strategies to overcome relapsed and refracto
Preface – ASH 2022
Preface – ASH 2022 © Lebens.Med Zentrum Bad Erlach
Real-world risk assessment, outcomes and adoption of novel drugs in CLL patients: insights from US databases
Real-world risk assessment, outcomes and adoptio
